Summary: Findings revealed a profound therapeutic benefit: GLP-1 receptor agonists (such as semaglutide, tirzepatide, and liraglutide) do not merely drive physical weight reduction. Instead, they actively downregulate the core behavioral…
- Thursday, July 16, 2026
